SMBC Nikko Securities Starts Arrowhead Pharma (ARWR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $60.73 --0%
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Rating Summary:
18 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 15
Join SI Premium – FREE
SMBC Nikko Securities analyst David Hoang initiates coverage on Arrowhead Pharma (NASDAQ: ARWR) with a Outperform rating and a price target of $80.00.
For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.
Shares of Arrowhead Pharma closed at $33.58 yesterday.
You May Also Be Interested In
- Chardan Starts Gossamer Bio Inc. (GOSS) at Buy
- Wells Fargo Assumes Globant S.A. (GLOB) at Equal Weight
- Citizens Starts Ascentage Pharma Group (AAPG) at Market Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
